Improving Healthcare Through Cell-based Interceptive Medicine
Our group seeks to improve healthcare by participating to the development of "cell-based interceptive medicine", a new medical paradigm aimed at understanding the early molecular events that cause cells to deviate from a healthy to a disease trajectory, thereby generating biomarkers for the early detection of disease, and novel drug targets and innovative treatments to intercept disease before pathophysiology and symptoms appear.
We adopt a resolutely innovative modus operandi, which contributes to shaking up our classic methods by creating a transdisciplinary and open ecosystem where totally distinct approaches collide to allow both the study of the atomic structure of proteins and their organization in complex networks, both the analysis of microscopic model systems and of patient cohorts, both the screening of small molecules and their development to create affordable drugs.
To join our group as a graduate student or a postdoctoral fellow, please send a motivation letter and a complete CV by email directly to Benoit.Coulombe@ircm.qc.ca. Only candidates of interest will be contacted.
Development of COVID-19 antivirals that target the SARS.CoV.2-host protein interactome
Characterization of early molecular defects that cause rare diseases such as leukodystrophy
Discovery of small chemical compounds and peptides that correct early molecular defects causing leukodystrophies
Quantification of neurone surface receptors as biomarkers for neurodegenerative diseases
Function and mechanism of the PAQosome in protein complex assembly
Development of single-cell interactome imaging as a tool for interceptive medicine
10 MOST SIGNIFICANT DISCOVERIES FROM OUR LAB
Robert F, Douziech M, Forget D, Egly JM, Greenblatt J, Burton ZF, Coulombe B.
Wrapping of promoter DNA around the RNA polymerase II initiation complex induced by TFIIF.
Mol Cell. 1998 Sep;2(3):341-51.
Jeronimo C, Forget D, Bouchard A, Li Q, Chua G, Poitras C, Thérien C, Bergeron D, Bourassa S, Greenblatt J, Chabot B, Poirier GG, Hughes TR, Blanchette M, Price DH, Coulombe B.
Systematic analysis of the protein interaction network for the human transcription machinery reveals the identity of the 7SK capping enzyme.
Mol Cell. 2007 Jul 20;27(2):262-74.
Cloutier P, Lavallée-Adam M, Faubert D, Blanchette M, Coulombe B.
A newly uncovered group of distantly related lysine methyltransferases preferentially interact with molecular chaperones to regulate their activity.
PLoS Genet. 2013;9(1):e1003210.
Thiffault I, Wolf NI, Forget D, Guerrero K, Tran LT, Choquet K, Lavallée-Adam M, Poitras C, Brais B, Yoon G, Sztriha L, Webster RI, Timmann D, van de Warrenburg BP, Seeger J, Zimmermann A, Máté A, Goizet C, Fung E, van der Knaap MS, Fribourg S, Vanderver A, Simons C, Taft RJ, Yates JR 3rd, Coulombe B, Bernard G.
Recessive mutations in POLR1C cause a leukodystrophy by impairing biogenesis of RNA polymerase III.
Nat Commun. 2015 Jul 7;6:7623.
Cloutier P, Poitras C, Durand M, Hekmat O, Fiola-Masson É, Bouchard A, Faubert D, Chabot B, Coulombe B.
R2TP/Prefoldin-like component RUVBL1/RUVBL2 directly interacts with ZNHIT2 to regulate assembly of U5 small nuclear ribonucleoprotein.
Nat Commun. 2017 May 31;8:15615.
Houry WA, Bertrand E, Coulombe B.
The PAQosome, an R2TP-Based Chaperone for Quaternary Structure Formation.
Trends Biochem Sci. 2018 Jan;43(1):4-9.
Coulombe B, Cloutier P, Gauthier MS.
How do our cells build their protein interactome?
Nat Commun. 2018 Jul 27;9(1):2955.
Gauthier MS, Awan Z, Bouchard A, Champagne J, Tessier S, Faubert D, Chabot K, Garneau PY, Rabasa-Lhoret R, Seidah NG, Ridker PM, Genest J, Coulombe B.
Posttranslational modification of proprotein convertase subtilisin/kexin type 9 is differentially regulated in response to distinct cardiometabolic treatments as revealed by targeted proteomics.
J Clin Lipidol. 2018 Jul-Aug;12(4):1027-1038.
Cloutier P, Poitras C, Faubert D, Bouchard A, Blanchette M, Gauthier MS, Coulombe B.
Upstream ORF-Encoded ASDURF Is a Novel Prefoldin-like Subunit of the PAQosome.
J Proteome Res. 2020 Jan 3;19(1):18-27.
Djurdja Djordjevic, Maxime Pinard, Marie-Soleil Gauthier, Constance Smith-Hicks, Trevor L. Hoffman, Nicole I. Wolf, Renske Oegema, Ellen van Binsbergen, Berivan Baskin, Geneviève Bernard, Sébastien Fribourg, Benoit Coulombe, Grace Yoon.
De novo variants in POLR3B cause ataxia, spasticity, and demyelinating neuropathy.
The American Journal of Human Genetics. 2021 Jan 7; 186–193.
L’Institut de recherches cliniques de Montréal n’est pas responsable du contenu de ce site Web.
The Montreal Clinical Research Institute is not responsible for the content of this website.